- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04701164
Efficacy and Safety of ANX005 in Subjects With Guillain-Barré Syndrome
March 7, 2023 updated by: Annexon, Inc.
A Randomized, Double-blind, Placebo-controlled Phase 3 Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of ANX005 in Subjects With Guillain-Barré Syndrome
This study is intended to evaluate the efficacy and safety of ANX005 administered by intravenous (IV) infusion to participants recently diagnosed with Guillain-Barré Syndrome (GBS).
The total duration of study participation is approximately 6 months.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
216
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Dhaka, Bangladesh
- Recruiting
- National Institute of Neurosciences and Hospital (NINS)
-
Contact:
- Zhahirul Islam, MD
-
Dhaka, Bangladesh
- Recruiting
- Dhaka Medical Center
-
Contact:
- Zhahirul Islam, MD
-
-
-
-
-
Baguio, Philippines
- Recruiting
- Baguio General Hospital Medical Center
-
Batangas, Philippines
- Recruiting
- Batangas Medical Center
-
Batangas, Philippines
- Recruiting
- Mary Mediatrix Medical Center
-
Cebu City, Philippines
- Recruiting
- Perpetual Succour Hospital
-
Cotabato, Philippines
- Recruiting
- Cotabato Regional Medical Center
-
Davao, Philippines
- Recruiting
- Southern Philippines Medical Center
-
Manila, Philippines
- Recruiting
- Jose R. Reyes Memorial Medical Center
-
Manila, Philippines
- Recruiting
- West Visayas State University Medical Center
-
Zamboanga, Philippines
- Recruiting
- Zamboanga City Medical Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years and older (Child, Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Diagnosis of GBS according to the National Institute of Neurological Disorders and Stroke Diagnostic Criteria for Guillain-Barré Syndrome.
- Onset of GBS-related weakness ≤10 days prior to start of infusion.
- GBS-DS score of 3,4, or 5 at screening and at Day 1 prior to infusion.
Exclusion Criteria:
- Clinically significant findings on the screening electrocardiogram (ECG), laboratory test results, or physical examination that are not specific to GBS that may interfere with the conduct of the study, the interpretation of the data, or increase the participant's risk.
- Body weight <30 kilograms (kg) or >150 kg at screening.
- Unresponsive (inexcitable) nerve conduction study results in all nerves tested during screening.
- Previous or intended treatment with either plasma exchange or intravenous immunoglobulin for GBS.
- Diagnosis of a variant of GBS, including Miller Fisher syndrome, Bickerstaff's encephalitis, and overlap syndromes.
- History of prior episode of GBS.
- GBS-related weakness that improved since symptom onset, including an improvement between screening and Day 1 (baseline).
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: ANX005 Treatment Group - Dose 1
Participants will receive a single IV infusion of ANX005 (Dose 1) on Day 1.
|
Solution for intravenous infusion
|
Experimental: ANX005 Treatment Group - Dose 2
Participants will receive a single IV infusion of ANX005 (Dose 2) on Day 1.
|
Solution for intravenous infusion
|
Placebo Comparator: Placebo Group
Participants will receive a single IV infusion of placebo on Day 1.
|
Solution for intravenous infusion
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
GBS Disability Score (GBS-DS) at Week 8
Time Frame: Week 8
|
Week 8
|
|
Number of Participants with Adverse Events
Time Frame: Through Month 6
|
Number participants recently diagnosed with GBS who experience adverse events.
|
Through Month 6
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Medical Research Council (MRC) Sum Score at Week 8
Time Frame: Week 8
|
Week 8
|
MRC Sum Score at Day 8
Time Frame: Day 8
|
Day 8
|
Duration (Days) of Ventilation Support Over 26 Weeks
Time Frame: 26 weeks
|
26 weeks
|
GBS Disability Score (GBS-DS)
Time Frame: Week 26
|
Week 26
|
Number of Participants Requiring Intensive Care Unit Stay
Time Frame: 26 weeks
|
26 weeks
|
Duration (Days) of Intensive Care Unit Stays
Time Frame: 26 weeks
|
26 weeks
|
Patient Global Impression of Change Scores
Time Frame: Week 8 and Week 26
|
Week 8 and Week 26
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Clinical Trials, Annexon, Inc.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
December 17, 2020
Primary Completion (Anticipated)
April 30, 2024
Study Completion (Anticipated)
April 30, 2024
Study Registration Dates
First Submitted
January 6, 2021
First Submitted That Met QC Criteria
January 7, 2021
First Posted (Actual)
January 8, 2021
Study Record Updates
Last Update Posted (Estimate)
March 9, 2023
Last Update Submitted That Met QC Criteria
March 7, 2023
Last Verified
March 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ANX005-GBS-02
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Guillain-Barre Syndrome
-
Mansoura University HospitalUnknownGuillain Barre SyndromeEgypt
-
University Hospital, Basel, SwitzerlandRecruitingGuillain-Barre Syndrome (GBS)Switzerland
-
Ning Wang, MD., PhD.Recruiting
-
Mansoura University Children HospitalCompletedGuillain Barre SyndromeEgypt
-
Hoffmann-La RocheChugai Pharmaceutical Co., Ltd. (Sponsor in Taiwan and Japan)Withdrawn
-
Annexon, Inc.International Centre for Diarrhoeal Disease Research, Bangladesh; ResearchPoint...CompletedGuillain-Barré SyndromeDenmark, Bangladesh
-
International Centre for Diarrhoeal Disease Research...Erasmus Medical Center; GBS-CIDP Foundation International; National Institute...CompletedGuillain-Barré SyndromeBangladesh
-
Nihon Pharmaceutical Co., LtdCompletedGuillain-Barré SyndromeJapan
-
NHS Greater Glasgow and ClydeUniversity of GlasgowUnknownGullian Barre SyndromeUnited Kingdom
-
Cellenkos, Inc.Withdrawn
Clinical Trials on ANX005
-
Annexon, Inc.RecruitingAmyotrophic Lateral SclerosisUnited States, Canada
-
Annexon, Inc.CompletedHuntington DiseaseUnited States
-
Annexon, Inc.CompletedWarm Autoimmune Hemolytic Anemia (wAIHA)United States
-
Annexon, Inc.TerminatedSafety and Tolerability in Healthy VolunteersAustralia
-
Annexon, Inc.International Centre for Diarrhoeal Disease Research, Bangladesh; ResearchPoint...CompletedGuillain-Barré SyndromeDenmark, Bangladesh